6 For plan sponsors, the arrival of oral options means usage could grow, reinforcing the need for comprehensive utilization-management strategies
What you build on that foundation determines whether you track with the trial averages, exceed them, or fall below
Therefore, it is essential to carefully define the appropriate patient population and timing of intervention in future studies
Several options may reduce costs, including manufacturer savings programs (Novo Nordisk offers a Wegovy savings card for eligible patients), insurance prior authorization for Wegovy, and in some cases compounded semaglutide through a licensed pharmacy (note: compounded medications are not FDA-approved
No weak excuses
However, we might perhaps consider them in an individual with a higher BMI and a majority of glucose readings above target